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Abstract
Introduction: Symptomatic vaginal discharge is a common gynecological condition managed 
syndromically in most developing countries. In Zimbabwe, women presenting with symptomatic 
vaginal discharge are treated with empirical regimens that commonly cover both sexually 
transmitted infections (STI) and reproductive tract infections, typically including a combination of 
an intramuscular injection of kanamycin, and oral doxycycline and metronidazole regimens. This 
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study was conducted to determine the current etiology of symptomatic vaginal discharge and 
assess adequacy of current syndromic management guidelines.
Methods: We enrolled 200 women with symptomatic vaginal discharge presenting at 6 STI 
clinics in Zimbabwe. Microscopy was used to detect bacterial vaginosis and yeast infection. 
Nucleic acid amplifications tests were used to detect Neisseria gonorrhoeae, Chlamydia 
trachomatis, Trichomonas vaginalis and Mycoplasma genitalium. In addition, serologic testing 
was performed to detect HIV infection.
Results: Of the 200 women, 146 (73%) had an etiology detected, including bacterial vaginosis 
(24.7%); N. gonorrhoeae (24.0%); yeast infection (20.7%); T. vaginalis (19.0%); C. trachomatis 
(14.0%) and M. genitalium (7.0%). Among women with STIs (N=90), 62 (68.9%) had a single 
infection, 18 (20.0%) had a dual infection and 10 (11.1%) had three infections.
Of 158 women who consented to HIV testing, 64 (40.5%) were HIV infected.
The syndromic management regimen covered 115 (57.5%) of the women in the sample who had 
gonorrhea, chlamydia, M. genitalium, or bacterial vaginosis, while 85 (42.5%) of women were 
treated without such diagnosis.
Conclusion: Among women presenting with symptomatic vaginal discharge, bacterial vaginosis 
was the most common etiology and gonorrhea was the most frequently detected STI. The current 
syndromic management algorithm is suboptimal for coverage of women presenting with 
symptomatic vaginal discharge; addition of point of care testing could compliment the 
effectiveness of the syndromic approach.
Brief Summary:
Among women presenting with symptomatic vaginal discharge at primary health clinics in 
Zimbabwe, bacterial vaginosis (24.7%) and N. gonorrhoeae infection (24%) were the most 
common etiologies.
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Introduction
Symptomatic vaginal discharge is a common gynecological condition among women of 
child bearing age accounting for an estimate of 5–10 million clinic visits per year throughout 
the world.1 Vaginal discharge may be a normal occurrence in pregnancy, menstruation or use 
of estrogen containing hormonal contraception.2–4 Abnormal vaginal discharge occurs 
commonly among women with bacterial vaginosis, candidiasis, trichomoniasis, chlamydia 
and gonorrhea.2,5 The presence of abnormal vaginal discharge may also be associated with 
multiple adverse reproductive tract outcomes that include pelvic inflammatory disease, 
infertility, ectopic pregnancy, chronic pelvic pain, and a greater than 2–3 fold increased risk 
of HIV acquisition.6–10 In most clinical settings, the management of vaginal discharge is 
mainly syndrome driven and empirical due to limited point-of-care diagnostic tools to 
differentiate causative etiologies.4,7,10–12 These empirical regimens commonly cover a 
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spectrum of pathogens that are identifiable causes of sexually transmitted infections (STIs) 
and reproductive tract infections (RTIs). RTIs are typically endogenous infections caused by 
overgrowth of organisms present in the genital tract.
In 2015, a total of 252,406 adult STI cases were reported syndromically to the Zimbabwe 
Ministry of Health and Child Care of which 79,371 (31.4%) were women with vaginal 
discharge (unpublished data). The 2013 Zimbabwe STI treatment guidelines recommend 
that all women presenting with vaginal discharge should receive a course of oral 
metronidazole tablets (400mg or 500mg orally, 3 times a day for 7 days OR 2g orally, single 
dose) as empirical treatment for bacterial vaginosis and trichomoniasis. Additional anti-
fungal treatment using miconazole (200mg vaginal pessaries once at night for 3 days) or 
clotrimazole vaginal tablet (100mg at night for 7 days) is only indicated when clinical 
manifestations of candidiasis are apparent. Women presenting with muco-purulent vaginal 
discharge are recommended a regimen that includes kanamycin (2 grams intramuscularly, 
single dose) or ceftriaxone (250mg intramuscularly, single dose) in addition to doxycycline 
(100mg orally, twice a day for 7 days) as empirical treatment for Neisseria gonorrhoeae and 
Chlamydia trachomatis.13
Syndromic management of symptomatic vaginal discharge is based on clinical signs and 
symptoms with potential risk of overtreatment and development of antimicrobial resistance 
in the absence of identified etiological organism.1,4,7,10 To monitor epidemiological shifts in 
the etiology of vaginal discharge, it is essential to conduct periodic surveys to provide 
evidence based treatment strategies to policy makers.12
The purpose of this study was to establish the etiology of vaginal discharge syndrome 
among women presenting with symptoms of vaginal discharge in Zimbabwean clinics. The 
results will be used to assess the continued applicability of existing syndromic treatment 
guidelines in Zimbabwe.
Materials and Methods
Study design
This is a sub-study of the Zimbabwe STI Etiology study conducted in 2014 – 2015 whose 
main objective was to establish the etiology of STI syndromes in Zimbabwe, including male 
urethral discharge syndrome, male and female genital ulcer disease, and vaginal discharge 
syndrome. Results of the urethral discharge and genital ulcer disease sub-studies have been 
published in this journal previously14,15 and a general description or the study’s 
methodology and study population is available online.16 This manuscript reports on female 
study participants presenting with vaginal discharge.
The full study protocol including consent forms and questionnaires are available online.17 
Six regionally and ethnically diverse STI clinics were selected. Two clinics were selected 
from Harare (Mbare and Budiriro); two from Bulawayo (Nkulumane and Khami Road); one 
from border town Beitbridge (Dulibadzimu) and one from a rural community (Gutu 
Hospital). More details on clinic selection can be found in the study protocol.17
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Through convenience sampling, trained nurses recruited 200 consecutively eligible women 
aged 18–53 years presenting with vaginal discharge at the study clinics. Based on statistical 
considerations as well as limited resources available to the study, we felt that a sample size 
of 200 would strike an acceptable balance between available study resources and the need 
for precision.17
Sexually active women presenting with subjective complaints of abnormal vaginal discharge 
were included in the study. Patients were ineligible if they did not speak Shona, English or 
Ndebele (the 3 major languages spoken in Zimbabwe); if they were unable to provide 
consent; or if they had received treatment for STIs in the previous 4 weeks. Study enrolment 
was conducted from June 2014 to April 2015.
Study procedures
Patients who met the eligibility criteria underwent a consenting process and were asked to 
sign an informed consent form covering all study procedures. The study nurse then 
completed a paper copy questionnaire that included demographic information, sexual 
history, description of symptoms, history of STI/HIV and current use of medications. Each 
consenting patient underwent genital examination including speculum insertion and received 
vaginal discharge pH testing by a strip method. Four vaginal swabs were collected and one 
swab was used to make a smear for Gram stain. A blood sample was taken for HIV testing, 
among those who consented to this test. All patients were treated for STIs according to the 
2013 Zimbabwe STI treatment guidelines.13 Paper data were reviewed and transcribed into a 
computer based data system on hand held devices. Data were uploaded at least daily from 
study sites to an online secure central database.
Laboratory procedures
All specimens were kept refrigerated (2 – 8 °C) and shipped in a cooler box with cooling 
packs the same day or overnight to the receiving laboratory at Wilkins Hospital in Harare 
where the specimens were kept refrigerated until further processing. Vaginal swabs were 
stored in a freezer at −70°C and batched for shipment. One swab was shipped to the STI 
reference laboratory at the National Institute for Communicable Diseases (NICD) in 
Johannesburg, South Africa. At the NICD laboratory Neisseria gonorrhoeae, Chlamydia 
trachomatis, Trichomonas vaginalis and Mycoplasma genitalium were tested using an in-
house developed multiplex polymerase chain reaction (M-PCR) developed at the Centers for 
Disease Control and Prevention (Atlanta, United States).5 The other two vaginal swabs were 
shipped to two local laboratories to perform additional testing for N. gonorrhoeae and C. 
trachomatis by nucleic acid amplification testing (NAAT) using Becton Dickinson ProbeTec 
(BD Molecular Diagnostics, Franklin Lakes, NJ, USA) at the University of Zimabwe 
College of Health Science - Clinical Trial Unit Central Laboratory in the Obsterics and 
Gynaecology department of the University of Zimbabwe and using GeneXpert (Cepheid, 
Sunnyvale, CA, USA) at the Flowcytometry laboratory in Harare. For the purposes of 
comparisons with T. vaginalis and M. genitalium in this study, we only included results from 
the M-PCR. However, concordance between M-PCR with Probetec and GeneXpert (i.e., the 
3 tests were either all positive or all negative) was >95% for both gonorrhea and chlamydia. 
A comparative study has been presented elsewhere.18
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HIV testing was performed at the study laboratory at Wilkins Hospital in Harare using the 
standard rapid testing algorithm used in Zimbabwe.∗ Syphilis testing using treponemal and 
non-treponemal assays were also conducted, however reporting on results fell outside the 
scope of this manuscript and will be presented elsewhere. Gram staining was also conducted 
in the laboratory at Wilkins Hospital to diagnose candidiasis and bacterial vaginosis. 
Candidiasis was defined as the presence of budding yeast of pseudo-hyphae and bacterial 
vaginosis was diagnosed using the Nugent criteria19 ; a score of 0 – 3 was considered 
normal, a score of 4 – 6 was considered intermediate and a score of 7 – 10 was classified as 
bacterial vaginosis. While Gram stain is an insensitive test for gonorrhea, the presence of 
intracellular Gram-negative diplococci organisms on Gram stain was recorded. All testing 
was done using standard operating procedures. More detail on laboratory procedures can be 
found in the online supplement.17
Data analysis
Data on participant demographics and sexual health and STI history were analyzed using 
SAS software (Cary, NC, USA). Tests for statistical significance testing included Chi-Square 
and Fisher’s exact test for categorical variables and Student’s T-test for continuous variables.
Since we assumed the possibility of variations and clustering by clinic, we did not attempt to 
generalize the relative prevalence of pathogens and conditions associated with vaginal 
discharge in our study and hence do not present 95% confidence intervals.
For purposes of the analysis in this manuscript, clinics were combined into 3 regions: 
Harare, Bulawayo, and Beitbridge/Gutu.
Ethical considerations
The protocol, consent forms and questionnaires were reviewed and approved by the 
University of Zimbabwe Joint Research and Ethics Committee of Parirenyatwa Central 
Hospital, the Zimbabwe Medical Research Council and the U.S Centers for Disease Control 
and Prevention.
Results
Demographics and Risk Factors
Selected demographic characteristics and risk factors among women presenting with vaginal 
discharge are presented in Table 1. Of the 200 enrolled women, 69 (34.5%) were from 
Harare including 19 pregnant women, 69 (34.5%) were from Bulawayo including 1 pregnant 
woman, 59 (29.5%) were from Beitbridge and 3 (1.5%) from Gutu. Women recruited were 
predominantly Shona (63.5%), however, as expected women recruited in Bulawayo were 
significantly more Ndebele, given that Ndebele is the predominant population in the region. 
The mean and median ages were 27.6 years and 26 years respectively. Sixty-two percent of 
∗HIV testing in Zimbabwe follows a standard algorithm of the following HIV rapid tests: 1) initial test by First Response HIV 1–2.O 
(Premier Medical Corporation, Daman, India); 2) confirmatory test by Alere Determine HIV 1/2 (Alere, Waltham MS, USA) if the 
initial test result is positive, and 3) INSTI HIV1/HIV2 (Biolytical, Richmond BC, Canada) as a tiebreaker if the initial and 
confirmatory tests are discrepant.
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women were married and only 12.5% were employed. Previous history of STI was reported 
among 27.9% of the patients. In the preceding 3 months, 7.5% of women reported multiple 
sex partners while 8.5% reported sex work. Absence of condom use at last sex with main 
and casual partner was reported by 71.6% and 66.9% of women respectively. Participants 
from Beitbridge or Gutu were significantly more likely to report sex work and having more 
than one partner in the previous 3 months.
Gram Stain Results
Gram stain results were available for 198 women. Nugent scores were as follows: 0–3: 75 
(37.9%); 4–6: 70 (35.3%) and 7–10: 53 (26.8%). Forty-one (20.7%) women had Gram stain 
evidence of yeast infections and 18 (9.1%) women had evidence of gonorrhea. When 
excluding women with a Gram stain diagnosis of yeast infection or gonorrhea, 49 women 
(24.7%) were diagnosed with bacterial vaginosis based on a Nugent score of 7 or higher and 
90 (45.5%) had a normal Gram stain.
Multiplex Polymerase Chain Reaction (M-PCR) Results
M-PCR results were available for all 200 women and pathogens were detected in 90 women 
(45.0%), including N. gonorrhoeae (48/200, 24.0%), T. vaginalis (38/200, 19.0%), C. 
trachomatis (28/200, 14.0%) and M. genitalium (14/200, 7.0%). There were no significant 
variations in prevalence of STI etiologies across recruitment sites (Table 2). All 18 women 
with gonorrhea identified on Gram stain tested positive for N. gonorrhoeae by M-PCR.
Of the 90 women who had pathogens identified, 62 (68.9%) had a single infection, 18 
(20.0%) had a dual infection and 10 (11.1%) had three infections (Figure 1). Most co-
infections were a combination of gonorrhea with chlamydia and trichomonas (n=9); 
gonorrhea and chlamydia (n=7) and gonorrhea and trichomonas (n=6). In addition, 24/49 
(49%) of women with bacterial vaginosis but only 10/41 (24.4%) of women with candidiasis 
had at least one STI (p<0.05).
When analyzing the etiology of vaginal discharge in our study by each component of the 
typical syndromic management for this condition (i.e., a combination of kanamycin, 
doxycycline and metronidazole), the kanamycin component covered 48 (24.0%) women in 
the sample who had gonorrhea, the doxycycline component covered 60 (30.0%) women who 
either had gonorrhea or chlamydia, and the metronidazole component covered 77 (38.5) of 
women who either had bacterial vaginosis or trichomoniasis. Combined, the syndromic 
management regimen covered 115 (57.5%) of the women in the sample who had gonorrhea, 
chlamydia, M. genitalium, trichomoniasis or bacterial vaginosis, while 85 (42.5%) of 
women were treated without such diagnosis. The treatment components in the current 
algorithm13 did not include a macrolide; therefore 14/200 (7%) of women with Mycoplasma 
genitalium may have received sub-optimal treatment.
PH
PH assessment was available for 191/200 (95.5%) of women. The mean PH was 5.2 (median 
5.3, interquartile range 0.5). Using the median PH value, 82 women (42.9%) had a PH lower 
than 5.3 and 109 (57.1%) had a PH of 5.3 or higher. Only 8 women in the study had a PH of 
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≤ 4.5. Associations of PH at the 5.3 cut-off with etiologic conditions linked to vaginal 
discharge is presented in Table 3. Higher PH was statistically significantly associated with a 
diagnosis of BV and gonococcal infection and marginally associated with chlamydial 
infection. Lower PH was associated with yeast infection or normal findings. There was no 
association with trichomonas infection. Performance of the PH test (at the 5.3 cut-off) to 
predict any condition covered under the syndromic guidelines (i.e., BV or infection with N. 
gonorrhoeae, C. trachomatis, T. vaginalis, or M. genitalium) were as follows: sensitivity: 
73/108 (67.6%); specificity: 47/83 (56.6%); predictive value of a high PH: 73/109 (67.0%); 
predictive value of low PH: 47/82 (57.3%).
HIV Infection
Of the 158 women who consented to HIV testing, 64 (40.5%) were HIV infected. The 
burden of STIs was higher amongst women with HIV infection compared to HIV uninfected 
women (54.7% versus 37.2%, p<0.05). Table 4 shows association of HIV with STIs and 
RTIs. Women with T. vaginalis infection were more likely to be HIV infected than women 
without T. vaginalis infection (59.4% versus 35.7%, p < 0.05). Women with gonorrhea were 
also more likely to be HIV infected compared to women without gonorrhea (54.1% versus 
36.4%, p = 0.05). Although not significantly different, women with chlamydia infection 
were less likely to be HIV infected compared to women without chlamydia infection (22.7% 
versus 43.4%, p=0.06), however this association disappeared when controlling for age (data 
not shown).
There was no association between HIV infection and diagnosis of bacterial vaginosis or 
yeast infection.
DISCUSSION
The purpose of this sub-study was to establish the etiology of vaginal discharge syndrome 
among women presenting to selected Zimbabwe STI clinics, in order to assess the adequacy 
of current treatment guidelines against the prevalent causes of vaginal discharge.
Bacterial vaginosis (24.7%) was the most prevalent cause identified among women 
presenting with vaginal discharge syndrome. The predominance of bacterial vaginosis as a 
common cause of vaginal discharge syndrome is an observation that has been reported in 
several other studies among women with reproductive tract infections.4–7,10 Detection of 
STIs by M-PCR was most common for N. gonorrhoeae (24.0%), T. vaginalis (19.0%) and C. 
trachomatis (14.0%). The observed higher burden of N. gonorrhoeae compared to C. 
trachomatis in our study is in contrast to previous studies amongst asymptomatic women 
conducted in Zimbabwe20,21 and in sub -Saharan Africa which revealed a higher burden of 
C. trachomatis than N. gonorrhoeae.22 This could be a manifestation resulting from the more 
symptomatic nature of gonorrhea than chlamydia, such that women infected with N. 
gonorrhoeae are more likely to present to a health care facility.23
The presence of multiple concurrent infections was most commonly identified among 
women infected with N. gonorrhoeae, C. trachomatis and T. vaginalis, a manifestation that 
typically presents with muco-purulent vaginal discharge. This study also reveals presence of 
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M. genitalium (7.0%). This organism has been reported as a cause of STI in several 
countries and an association with HIV has been reported.24–26 Replacing doxycycline with 
azithromycin in the syndromic treatment algorithm may increase coverage for M. genitalium 
while still providing adequate coverage for chlamydia (azithromycin is currently listed as an 
alternative regimen in the Zimbabwe STI treatment guidelines13). However a 23S rRNA 
mutation in the M. genitalium ribosome has resulted in rapidly increasing macrolide 
resistance world-wide, especially in countries that have replaced doxycycline with 
azithromycin in their STI treatment guidelines, leaving a conundrum for appropriate 
syndromic management and providing another rationale for etiologic testing.27
A significant number of women presenting with vaginal discharge syndrome were HIV 
infected (40.5%) compared to HIV prevalence of 15.6% in the general population.28 The 
burden of STIs was higher amongst HIV-infected women (54.7% versus 37.2%, p<0.05). 
Trichomoniasis was significantly associated with HIV infection, an observation that has 
been reported in previous studies.29 These data support a recommendation that the 
Zimbabwe Ministry of Health and Child Care should consider offering HIV testing and 
linkage to care for all women presenting with symptomatic vaginal discharge. In addition to 
prompt treatment of STI, partner management for women diagnosed with STI is also crucial 
to prevent re-infection and on-going transmission.12,30,31
With regards to the adequacy of syndromic management for vaginal discharge syndrome, 
our study found that 57.5% of women had a pathogen covered by a combination treatment of 
kanamycin, doxycycline, and metronidazole. However, the kanamycin component over-
treated 76% of women who did not have gonorrhea; the doxycycline component over-treated 
70% of women who did not have gonorrhea or chlamydia and the metronidazole component 
over-treated 61.5% of women who did not have bacterial vaginosis or trichomoniasis. 
Moreover, treatment for M. genitalium may have been sub-optimal. Our results are in 
agreement with several studies that have observed a relatively low positive predictive value 
for the detection of STI when using the vaginal discharge syndrome algorithm5,10,11,30 with 
potential harm for over treatment, anti-microbial resistance and stigmatization. To avoid the 
burden of over treatment, there is need for diagnostic capacity at the clinics thus affordable 
point of care testing32 should be considered for STI screening among women presenting 
with symptomatic vaginal discharge, including basic microscopy to differentiate BV, 
trichomoniasis, and yeast infections. Also, point of care testing using nucleic acid 
amplification technology that is increasingly becoming available for tuberculosis/rifampin 
resistance testing in developing countries, can easily be utilized for chlamydia and 
gonorrhea testing on the same platform.
Vaginal PH testing is a simple and cheap test that could be used in the diagnostic 
differentiation of the vaginal discharge syndrome at the point on of care. Indeed, we found 
statistically significant associations between a PH ≥ 5.3 and BV or infection with N. 
gonorrhoeae. However, for practical purposes, the diagnostic differentiation proved to be 
inadequate: while the positive predictive value was quite high (67%) for women with a high 
PH who had BV or STI, the negative predictive value was low (i.e., 42.7% of women with a 
low PH still had BV or STI).
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Given the high burden of STIs amongst HIV-infected women and the high level of 
concurrent STIs, there is a high risk of ongoing HIV transmission in this community. In 
addition to capacitating clinics with STI point-of-care testing, the Zimbabwe Ministry of 
Health and Child Care should consider expanding programs that promote HIV risk 
reduction. These include condom use promotion and antiretroviral treatment (ART) 
counseling. Adherence to ART reduces viral load thereby reducing the chances of HIV 
transmission to sexual partners33. In addition, partners should be offered HIV testing; HIV 
negative partners should be encouraged to take up pre-exposure prophylaxis to reduce HIV 
infection34 and HIV positive partners should be encouraged to initiate ART as per WHO 
guidelines.35
Our study should be understood in light of some limitations. First, for the diagnosis of yeast 
infection and bacterial vaginosis, the study relied on Gram stain testing; on-site wet mount 
testing was not conducted. This could have resulted in an under-estimation of both 
conditions. Moreover, 35% of women had intermediate (4–6) Nugent scores and in one 
study 32% of women with intermediate scores progressed to bacterial vaginosis , whereas 
30% reverted to normal flora.36 Second, this study did not determine antibiotic susceptibility 
to confirm the effectiveness of the empirical regimens as recommended by the current local 
guidelines particularly for N. gonorrhoeae.13 However, a recent study conducted in 
Zimbabwe showed high levels of N. gonorrhoeae susceptibility to kanamycin and 
ceftriaxone20 and additional studies are ongoing. Third, this study only enrolled 
symptomatic women that could have resulted in a bias towards a high prevalence of STIs 
and these results can therefore not be generalized to asymptomatic women; thus requiring 
additional studies amongst the latter population.
In view of the 42.5% of women with symptomatic vaginal discharge who were over-treated 
using the current algorithm, we recommend a review of the Zimbabwean STI treatment 
algorithm with a focus on point of care testing. Point of care testing, especially the use of 
nucleic acid amplification testing devices that are becoming increasingly available, would 
also allow for testing of asymptomatic women. Because STIs among women, including 
gonorrhea and chlamydia infections are often asymptomatic, such an approach would have a 
greater impact on STI control than the current approach depending on syndromic 
management.
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Figure 1: Frequency of co-infections between various pathogens among women
Key: NG - N. gonorrhoeae; TV - T. vaginalis; CT - C. trachomatis; MG - M. genitalium
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Table 1:
Demographics and Risk Factors Among Women Presenting with Vaginal Discharge
All clinics % Harare % Bulawayo % Beitbridge/Gutu % P
Evaluable Participants 200 69 34.5 69 34.5 62 31.0
Ethnicity
Shona 127 63.5 66 95.7 14 20.3 47 75.8 <0.0001
Ndebele 57 28.5 2 2.9 49 71.0 6 9.7
Other 16 8.0 1 1.4 6 8.7 9 14.5
Age
Mean 27.6 - 27.4 - 28.1 - 27.3 - NS
Median 26.0 - 26.0 - 25.0 - 26.0 -
Age Category (Years)
15–19 17 8.5.5 4 5.8 7
25
10.2 6 9.7 NS
20–24 64 32.0 23 33.3 25 36.2 16 25.8
25–29 49 24.5 18 26.1 11 15.9 20 32.3
30–34 36 18.0 13 18.8 13 18.8 10 16.1
35–39 20 10.0 8 11.6 5 7.3 7 11.3
≥40 14 7.0 3 4.4 8 11.6 3 4.8
More than 1 partner in previous 3 
months
No 185 92.5 67 97.1 67 97.1 51 82.3 <0.01
Yes 15 7.5 2 2.9 2 2.9 11 17.7
Sex work in previous 3 months
No 183 91.5 64 92.8 67 97.1 52 83.9 <0.05
Yes 17 8.5 5 7.2 2 2.9 10 16.1
Condom use at last sex with main 
partner*
No 141 71.6 54 78.3 48 72.7 39 62.9 NS
Yes 56 28.4 15 21.7 18 27.3 23 37.1
Missing 3 0 3 0
Condom use at last sex with casual 
partner*
No 107 66.9 29 80.6 42 67.7 36 58.1 NS
Yes 53 33.1 7 19.4 20 32.3 26 41.9
Missing 40 33 7 0
Perceived HIV Status
Negative 55 27.5 17 24.6 24 34.8 14 22.6 NS
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All clinics % Harare % Bulawayo % Beitbridge/Gutu % P
Evaluable Participants 200 69 34.5 69 34.5 62 31.0
Positive 64 32.0 16 23.2 22 31.9 26 41.9
Unknown 81 40.5 36 52.2 23 33.3 22 35.5
STI History
No 142 72.1 45 67.2 49 72.1 48 77.4 NS
Yes 55 27.9 22 32.8 19 27.9 14 22.6
Missing 3 2 1 0
Marital status
Married 124 62.0 57 82.6 37 53.6 30 48.4 <0.0001
Unmarried 76 38.0 12 17.4 32 46.4 32 51.6
Employed
Yes 25 12.5 8 11.6 10 14.5 7 11.3 NS
No 175 87.5 61 88.4 59 85.5 55 88.7
Pregnancy
Yes 20 10 19 27.5 1 1.5 0 0 <0.0001
No 180 90 50 72.5 68 98.5 62 100
*
Percentages and Chi Square/T-Test analyses limited to non-missing data
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Table 2:
Prevalence of STI Etiologies by Recruitment Site and Frequency of Co-Infections
All clinics Harare Bulawayo Beitbridge/ Gutu P
N % N % N % N %
Total 200 69 69 62
Pathogen
N. gonorrhoeae 48 24.0 13 18.8 17 24.6 18 29.0 NS
C. trachomatis 28 14.0 6 8.7 11 15.9 11 17.7 NS
T. vaginalis 38 19.0 10 14.5 17 24.6 11 17.7 NS
M. genitalium 14 7.0 5 7.2 4 5.8 5 8.1 NS
Any Infection 90 45.0 26 37.7 31 44.9 33 53.2 NS
No Infection 110 55.0 43 62.3 38 55.1 29 46.8 NS
Key: NG - N. gonorrhoeae; TV - T. vaginalis; CT - C. trachomatis; MG - M. genitalium
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Table 3.
PH Test Results* Among Women With Vaginal Discharge Syndrome
Test Performance**
N Prevalence (N/%) OR P Sensitivity Specificity PPV+ PPV−
Low PH High PH
Gram Stain 191 82 109
BV 45 12 (14.6) 33 (30.3) 2.5 (1.2–5.3) <0.05 73.3 47.3 30.3 85.4
Yeast 39 23 (28.0) 16 (14.7) 0.4 (0.2–0.9) <0.05 59.0 61.2 28.0 85.3
Normal 88 43 (52.4) 45 (41.3) 0.6 (0.4–1.1) NS 48.9 62.1 52.4 58.7
M-PCR 191 82 109
N. gonorrhoeae 45 13 (16.0) 32 (29.4) 2.2 (1.1–4.5) <0.05 71.1 47.3 29.4 84.0
C. trachomatis 27 7 (3.6) 20 (18.3) 2.4 (0.9–6.0) 0.06 74.1 45.7 18.3 91.4
T. vaginalis 36 14 (17.1) 22 (20.2) 1.2 (0.6–2.6) NS 61.1 43.9 20.2 82.9
M. genitalium 13 3 (3.7) 10 (9.2) 2.7 (0.9–9.9) NS 76.9 44.4 9.2 96.3
Any infection 86 29 (35.4) 57 (52.3) 2.0 (1.1–3.6) <0.05 66.3 50.5 52.3 64.6
Any infection or BV 108 35 (42.7) 73 (67.0) 2.7 (1.5–4.9) <0.01 67.6 56.6 67.0 57.3
*
Low PH: ≤ 5.2 ; High PH: >5.2
**
Low vs. high PH for all infections/conditions, except yeast infection and normal Gram stain
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Table 4:
Association of HIV with Sexually Transmitted Infections and Reproductive Tract Infections
Number tested No. HIV Infected % P-value
Total 158 64
N. gonorrhoeae
Yes 37 20 54.1 P=0.05
No 121 44 36.4
C. trachomatis
Yes 22 5 22.7 P= 0.06
No 136 59 43.4
M. genitalium
Yes 12 7 58.3 NS
No 146 57 39
T. vaginalis
Yes 32 19 59.4 P<0.05
No 126 45 35.7
Any infection
Yes 70 35 50 P<0.05
No 88 29 32.9
Bacterial vaginosis*
Yes 39 15 38.5 NS
No 74 29 39.2
Yeast infection*
Yes 31 12 38.7 NS
No 74 29 39.2
*Compared to normal Gram Stain
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